跳至主要内容
临床试验/NCT07343297
NCT07343297招募中不适用

Ask Questions About Clinical Trials (ASQ - CT): An Implementation Trial of a Communication Intervention to Improve Patient-Provider Communication About Clinical Trials and Provider Invitations to Clinical Trials

Barbara Ann Karmanos Cancer Institute8 个研究点 分布在 1 个国家目标入组 293 人开始时间: 2026年12月30日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
293
试验地点
8
主要终点
Effectiveness - Self-Efficacy in managing patient-provider interactions - Quantitative Scale

研究概览

简要总结

The overall goal of this study is to assess the implementation of the Ask Questions about Clinical Trials (ASQ-CT) brochure, a patient-focused communication tool previously demonstrated to improve patient-provider communication about clinical trials. Participants will be given the ASQ-CT brochure at Time 1 (baseline) and participants will complete a questionnaire at three timepoints, baseline (Time 1), Pre-Research Visit (Time 2), and Post-Research Visit (Time 3).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age > or equal to 18 years
  • •Appointment to see a provider at a Karmanos Cancer Institute-McLaren or a medical encounter at McLaren Center for Research and Innovation (MCRI) site for medical/systemic treatment
  • •Potentially eligible for a clinical trial
  • •Speak and read English well enough to be able to understand consent documents and complete surveys

排除标准

  • •Not able to complete study documents on their own physically or cognitively

研究组 & 干预措施

Ask Questions about Clinical Trials (ASQ-CT) Brochure

Experimental

Ask Questions about Clinical Trials (ASQ-CT), a clinical trial communication intervention brochure

干预措施: Ask Questions about Clinical Trials brochure (Behavioral)

结局指标

主要结局

Effectiveness - Self-Efficacy in managing patient-provider interactions - Quantitative Scale

时间窗: From Baseline (Time 1) to end of Pre-Clinic Visit (Time 2)

Improvement of self-efficacy in managing patient-providers interactions between baseline (Time 1) and pre-clinic visit (Time 2). Measured using scale of 1-5 where a higher score is equal to a better outcome

次要结局

  • Reach - Number and Proportion(At start of Participation)
  • Effectiveness - Self-Efficacy in managing patient-provider interactions - Quantitative Scale(From Pre-Clinic (Time 2) to end of Post-Clinic Visit (Time 3) up to 3 months.)
  • Effectiveness - Knowledge - Quantitative Scale(From Baseline (Time 1) to end of Pre-Clinic Visit (Time 2))
  • Effectiveness - Knowledge - Quantitative Scale(From Pre-Clinic Visit (Time 2) to end of Post-Clinic Visit (Time 3) up to 3 months)
  • Effectiveness - Trust - Quantitative Scale(From Baseline (Time 1) to end of Pre-Clinic Visit (Time 2))
  • Effectiveness - Trust - Quantitative Scale(From Pre-Clinic Visit (Time 2) to end of Post-Clinic Visit (Time 3) up to 3 months)
  • Effectiveness - distress - Quantitative Scale(From Baseline (Time 1) to end of Pre-Clinic Visit (Time 2))
  • Effectiveness - distress - Quantitative Scale(From Pre-Clinic Visit (Time 2) to end of Post-Clinic Visit (Time 3) up to 3 months)
  • Adoption - Number and Proportion(At start of Participation)
  • Implementation of the Intervention(From Baseline (Time 1) to up to 3 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Lauren Hamel

Principal Investigator

Barbara Ann Karmanos Cancer Institute

研究点 (8)

Loading locations...

相似试验

已完成
1 期
This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adult participants with Chronic Inducible Urticaria (CIndU) to assess if it is safe and improves reactions to known CIndU triggers.Chronic Inducible Urticaria
2023-504800-28-00Escient Pharmaceuticals Inc.14
已完成
1 期
A clinical trial to learn how an investigational drug (norucholic acid) is absorbed, distributed, broken down, and removed from the body when given to people with kidney problemsNonalcoholic fatty liver disease (NAFLD)Primary sclerosing cholangitis (PSC)
2023-505862-27-00Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH48
招募中
1 期
A clinical trial to learn how an investigational drug (vimseltinib) is absorbed, distributed, broken down, and removed from the body when given to people with liver problemsTenosynovial Giant Cell Tumor (TGCT)Malignant Solid Tumors (MST)
2023-503415-15-00Deciphera Pharmaceuticals Inc.32
已完成
不适用
A Study to Assess the Effectiveness of a Marketed Denture Adhesive in Real-World SettingDenture Retention
NCT07273149HALEON375
已完成
1 期
This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body and if it can control the disease of people diagnosed with advanced cancer that has not responded to treatment, has returned after it has been treated, or cannot be treated by surgery, drugs, or any other known treatments.Part C: advanced or unresectable STs (Spain only)Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3)Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)
2023-509969-20-00Celgene Corp.127